14th Oct 2010 07:00
Change of Adviser and Broker
Oxford, UK - 14 October 2010: Oxford BioMedica ("the Company") (LSE: OXB), a leading gene therapy company, today announces that it has appointed Singer Capital Markets Limited as its corporate broker and financial adviser with immediate effect.
-Ends-
|
For further information, please contact: |
|
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Andrew Wood, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
|
Singer Capital Markets Limited: Shaun Dobson Claes Spång |
Tel: +44 (0)20 3205 7500
|
Notes to editors
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.
Related Shares:
Oxford Biomedica